

REVIEW

Open Access

# Genetic polymorphisms linked to susceptibility to malaria

Adel Driss<sup>1\*</sup>, Jacqueline M Hibbert<sup>1</sup>, Nana O Wilson<sup>1</sup>, Shareen A Iqbal<sup>2</sup>, Thomas V Adamkiewicz<sup>3</sup> and Jonathan K Stiles<sup>1\*</sup>

## Abstract

The influence of host genetics on susceptibility to *Plasmodium falciparum* malaria has been extensively studied over the past twenty years. It is now clear that malaria parasites have imposed strong selective forces on the human genome in endemic regions. Different genes have been identified that are associated with different malaria related phenotypes. Factors that promote severity of malaria include parasitaemia, parasite induced inflammation, anaemia and sequestration of parasitized erythrocytes in brain microvasculature.

Recent advances in human genome research technologies such as genome-wide association studies (GWAS) and fine genotyping tools have enabled the discovery of several genetic polymorphisms and biomarkers that warrant further study in host-parasite interactions. This review describes and discusses human gene polymorphisms identified thus far that have been shown to be associated with susceptibility or resistance to *P. falciparum* malaria. Although some polymorphisms play significant roles in susceptibility to malaria, several findings are inconclusive and contradictory and must be considered with caution. The discovery of genetic markers associated with different malaria phenotypes will help elucidate the pathophysiology of malaria and enable development of interventions or cures. Diversity in human populations as well as environmental effects can influence the clinical heterogeneity of malaria, thus warranting further investigations with a goal of developing new interventions, therapies and better management against malaria.

## Introduction: severity of malaria is influenced by host genetics

*Plasmodium falciparum* malaria is a major cause of mortality and morbidity, particularly in endemic areas of sub-Saharan Africa [1]. The disease aetiology is variable and is attributable to environmental factors, host genetics and parasite virulence [2]. Variations in severity of *P. falciparum* infections considered as different phenotypes include hyper or asymptomatic parasitaemia (proportion of red blood cells that are parasitized), severe malaria anaemia (SMA) and cerebral malaria (CM). Host genetic factors contribute to the variability of malaria phenotypes [3] and thus, should help to determine some of the mechanisms involved in susceptibility to *P. falciparum* infection. The knowledge gained since 1980s using molecular genetics approaches has produced undisputed evidence about polymorphisms associated

with malaria resistance and their complex interactions. Indeed, several gene mutations and polymorphisms in the human hosts confer survival advantage and have increased in frequency through natural selection over generations. These include sickle cell trait (HbAS) and haemoglobinopathies such as thalassaemias and glucose-6-phosphate dehydrogenase (G6PD) deficiency (Table 1) [4]. In the last decade, the development of molecular biology technologies and the completion of the human genome project have identified other loci that appear to directly or indirectly affect malaria susceptibility by modulation of the immune response, or by interfering with host-parasite interactions. This has provided insight into a dual process of natural selection and co-adaptation of polymorphisms occurring in the malaria parasite and its human host, to maintain genetic diversity. This review discusses recent findings on genetic modifiers shown to be significantly associated with and relevant to the diverse clinical outcomes of *P. falciparum* malaria. It is focused on the new gene polymorphisms found via genome-wide (GW) association studies (GWAS), case

\* Correspondence: adel@weboris.com; jstiles@msm.edu

<sup>1</sup>Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA

Full list of author information is available at the end of the article

**Table 1 Genetic mutations involved in susceptibility/resistance to *P.falciparum* malaria**

Gene (Symbol)	Phenotype	Proposed protective mechanisms	References
Haemoglobin C (HbC)	↓UM & ↓SM	Reduced cyto-adherence of infected erythrocytes	[29,47]
Haemoglobin E (HbE)	↓SM, ↓parasitaemia	Reduced erythrocyte invasion by merozoites, lower intra-erythrocytic parasite growth, and enhanced phagocytosis of infected erythrocytes.	[48,49]
Haemoglobin S (HbS)	↓UM & ↓SM	Selective sickling of infected sickle trait erythrocytes leading to enhanced clearance by the spleen. Reduced erythrocyte invasion, early phagocytosis, and inhibited parasite growth under oxygen stress in venous micro vessels. Enhancement of innate and acquired immunity.	[7,50]
α-thalassaemia (α-thal)	↓SM & ↓SMA	Reduced resetting. Increased micro-erythrocyte count in homozygotes reduces the amount of haemoglobin lost for given parasite density, thus protecting against severe anaemia.	[51-53]
β-thalassaemia (β-thal)	↓SM		[54,55]
Glucose-6-Phosphate dehydrogenase (G6PD)	↓UM & ↓SM	Increased vulnerability of the G6PD deficient erythrocyte to oxidant stress causes its protection against parasitization.	[56-59]
Pyruvate kinase (PKLR)	↓parasitaemia	Invasion defect of erythrocytes and preferential macrophage clearance of ring-stage-infected erythrocytes.	[60]
Ovalocytosis (SLC4A1)	↓SM & ↓CM	Inhibition of merozoite entry into the red cell, impairment of intracellular parasite growth and prevention of the erythrocyte lysis that occurs with parasite maturation, leading to release of merozoites into the blood stream.	[61,62]
Elliptocytosis	↓SM		[63]
Glycophorins A (GYP ABC)	↓SM		[64,65]
Blood Groups (ABO)	↓SM	Reduced <i>P. falciparum</i> rosetting.	[66-68]
Haptoglobin (HP)	↓SM	Oxidative damage to uninfected cells might be more marked in HP polymorphic individuals since HP proteins bind less efficiently to Hb, increasing premature destruction of erythrocytes and stimulating cytokine release by these circulating cells.	[69-71]
Nitric oxide synthase 2 (NOS2)	↓SM	Increased NO production induces Th1 cytokines which activate macrophages and could thus be an anti-malarial resistance mechanism.	[72,73]
haem oxygenase I (HO-1)	↓CM	Release of free haem in the blood stream.	[13,14]

control studies on different populations and provides new perspectives for the different studies presented.

#### Gene mutations involved in susceptibility and resistance to *P. falciparum* malaria

It has been shown that severity of several malaria infections (such as asymptomatic, CM and SMA) varies significantly between individuals and between populations [5]. Several gene mutations causing inherited diseases or traits have been reported to influence malaria severity (Table 1) [6]. Mutations in these genes have been linked to erythrocytes including haemoglobin (Hb) variants, or related to proteins such as haptoglobin and Nitric Oxide metabolism. For example, the heterozygote HbAS (sickle cell trait) which protects against severe malaria (SM) [7-10] is widespread in malaria endemic regions as a result of natural selection over generations [11]. It has also been shown that the rate limiting enzyme haem oxygenase I (HO-1), responsible for the catabolism of free haem in the body, plays an important moderator role in malaria and is also important in the pathophysiology of haemolytic diseases, such as sickle cell disease [12-15]. Epistatic interactions between genetic disorders

of haemoglobin (HbAS, thalassaemia, HbE, etc.) show evidence of heterozygote protection from malaria (Table 1) [16] and protection against malaria by the sickle cell trait is removed if there is co-inheritance of alpha-thalassaemia [17]. These studies emphasize the underlying complexity of the field and therefore stress the need for newer methods of genomic analysis. Although malaria resistance gene mutations have been well studied, genes associated with red cell disease severity deserve further scrutiny.

#### Genome-wide linkage and association studies in malaria

Some landmark genome wide linkage (GWL) and association studies (GWAS) have been conducted in recent years in African, European, Asian European and Asian populations. Application of GWAS to populations in Africa could provide insights into pathways controlling resistance to malaria as well as genetic origins of related diseases.

A GW gene expression study conducted by Griffiths *et al* [18] showed that a cluster of genes were expressed in correlation with absolute neutrophil count. The neutrophil-related gene region contained genes predicted to

encode mediators of innate and adaptive immunity, including those for cytokine receptors (IL1R2, IL18R1, and IL6R), Toll-like receptors (TLR1 and TLR4), heat-shock proteins (HSPA1A and HSPA1L), the acute-phase proteins ferritin (FTL) and alkaline phosphatase (ALPL), and intracellular signaling factors (NFKBIA, JUNB, and FOSL2). The region also contained genes linked with neutrophil activation, such as those for granulocyte colony-stimulating factor (G-CSF), a degranulation marker (CD66), and MAPK14 kinase. Many other genes, whose transcript levels were previously noted in human leukocyte models of *in vitro* bacterial infection, were also present (e.g., those for adrenomedullin, pre-B cell colony enhancing factor, and tumor necrosis factor-associated inducible protein) [18]. Based on changes in expression patterns of these genes, febrile and convalescent children could be assigned to distinct groups, indicating that neutrophil response plays a role in acute malarial infection. A second gene cluster was found to be associated with parasite density such that children with malaria could be distinguished from non-malaria patients, on the basis of different expression profiles. The cluster included genes encoding for pro-inflammatory molecules, markers of cellular stress and pro-apoptotic mediators [18]. Results also identified host gene responses (*HMOX1*, *HSPCB*, and *TNFRSF6*) that were related to the level of plasmodium parasitaemia. These studies identified several interesting candidate genes for further association studies to determine their roles in malarial immunity and pathogenesis.

GW linkage analyses of malaria infection severity revealed significant linkages to chromosome 10p15.3-14 and chromosome 13q [19]. Despite previous convincing results, no evidence of linkage was obtained for the 5q31 region to parasite density. Interestingly, a weak signal of linkage was observed for this region to malarial anaemia. The authors emphasized the difficulty of accurately defining the phenotype of malaria infection that could partially explain the divergence of linkage results [20].

Another GW linkage screening was carried out in a longitudinal survey of parasitological and clinical data from two independent Senegalese villages, Dielmo and Ndiop, that differ in ethnicity, malaria transmission and endemicity [21]. Analysis of several malaria-related phenotypes both during clinical disease and asymptomatic infection showed evidence of strong genetic contribution to both phenotypes studied. Asymptomatic parasite density showed linkage to chromosome 5q31, confirming previous findings [20]. Suggestive linkage values were also obtained: episodes of clinical malaria disease were linked to chromosome 5p15 and 13q13, while the maximum parasite density during asymptomatic infection was linked to chromosome 12q21. While regions of linkage showed little overlap with genes known to be

involved in SM, the four regions appeared to overlap with regions linked to asthma or atopy related traits, suggesting that common immune related pathways may be involved. These newly identified linkage regions are interesting, but will require validation by independent studies. Also, fine mapped association studies are required to identify the genes underlying these linkages [21]. Ockenhouse *et al* investigated aspects of the earliest responses to malaria infection at the molecular level, and suggested an important role of innate and adaptive immune responses in different stages of infection [22].

Several inter-ethnic comparative studies showed that the Fulani population from West Africa is more resistant to *P. falciparum* malaria than are other sympatric ethnic groups [23]. The analysis of the immune response to *P. falciparum* sporozoite and blood stage antigens, as well as non-malaria antigens, revealed higher immune reactivity in the Fulani and that higher resistance to malaria among them could derive from a functional deficit of T-regulatory cells [23]. In this study, the results suggest that T-regulatory cell activity could be central in the control of malaria infection also in populations exposed to naturally high *P. falciparum* transmission. Furthermore, this study highlights the existence of clear-cut differences in strategic pathways of the immunoregulatory network between sympatric populations differing in their genetic background and degree of susceptibility to malaria. A higher resistance against *P. falciparum* malaria could have been the driving selective force of this disorder.

Jallow *et al* conducted a GWAS of SM in 2,500 children from The Gambia, which was replicated in an additional 3,400 children [24]. Besides the considerable population stratification found, their result show that signals of association at known malaria resistance loci were greatly attenuated due to weak linkage disequilibrium (LD). Conversely, the GW association analysis did not identify any of the well-known erythrocyte variants that have been selected by malaria, other than HbS. They explained this partly by population genetic factors; for example, the Duffy FY\*O allele has reached fixation in The Gambia, whereas other variants, such as those affecting haemoglobin C and Southeast Asian ovalocytosis, are rare or absent in this population. No associations were found at *G6PD* and *HBA1-HBA2*, the loci for glucose-6-phosphate deficiency and  $\beta^+$ -thalassaemia, respectively, possibly due to the lack of fine mapping of the SNPs (single nucleotide polymorphisms) dataset within these regions. The group genotyped the SNP rs1050828, a *G6PD* coding polymorphism, that was suggested to be a marker for protection against SM [25]. The minor allele frequency of rs1050828 in the Gambian control sample was 0.03, considerably lower than

for samples from Kenya (0.18) and Malawi (0.19) [24]. The power to detect association with rs1050828 in The Gambia was affected by this low allele frequency, and the results were consistent with a modest protective effect although not statistically significant.

The rs8176719 genotype (a splice-site insertion in the *ABO* gene) is consistent with previous studies, which found that individuals of different populations who are not of blood group O, have 1.2-fold increased risk of SM [26]. Other SNP associations (on *CD36*, *CD40LG*, *CRI1*, *ICAM1*, *IL22*, *NOS2*, and *TNF*) have been reported for malaria, but have not been conclusively replicated in large studies across different populations, and are mostly thought to be markers rather than true causal variants. The authors attribute this in part to low tagging efficiency of the Affymetrix 500 K array used and low statistical power, particularly low allele frequencies. In addition, they identified several significant association regions other than *HBB* (Hb-beta locus): on chromosome 2q37 (with the closest genes *SPATA3*, *LOC257407*, *PSMD1* and *GPR55*), on chromosome 5p12 (in a region that has a number of genes encoding proteins of unknown function) and on chromosome 14q21 (in an area with few genes) [26]. Further investigations are needed to prove that polymorphisms in these genes significantly affect malaria outcomes.

#### **Gene polymorphisms associated with protection against *P. falciparum* malaria**

Recently published polymorphisms that are significantly associated with susceptibility and resistance to *P. falciparum* malaria are summarized in additional file 1. The large majority of the polymorphisms found in these reports were mainly genes directly or indirectly involved with host immunity, including human leukocyte antigen system (HLA) genes, cytokine genes, complement regulatory genes and endothelial receptor genes. These polymorphisms do not cause host genetic pathology themselves, but are associated with malaria severity. A description of the function of their corresponding gene products is summarized in Additional file 2.

Although malaria remains a devastating disease responsible for high global mortalities, only few association studies have been reported on malaria phenotypes and polymorphisms of candidate loci. It is well established that in some cases as in haemoglobinopathies, despite the lack of a consensus on the mechanism of protection, the actual protective role has been identified and solid epidemiological evidence has been reported (Table 1). However, much information remains to be obtained for many genes related to the red cell surface, oxidative stress, cyto-adherence and immune response associated with malaria. In fact, only a few of the associations reviewed in Additional file 1 have been tested

in independent studies in different populations and even when replication has been attempted, results have often been conflicting; either the initial finding could not be replicated or a polymorphism initially associated with increased risk of SM in a study was associated with protection against SM in another study. Finally, in some instances the genotypic and/or haplotypic patterns of association varied across different studies/populations (Additional file 1). These inconsistencies can be explained in several ways:

#### **Sample size and source**

It has been established that GW screening conducted on large sample sizes and in multiple populations have greater potential to be more informative. Sometimes, the lack of association can be a false negative result due to lack of statistical power. Another difficulty is that in most cases, when population based phenotype-genotype relationships are studied, it is assumed that the population is genetically isolated. The extensive genomic diversity within Africa and across different continents complicates the situation. Association signals for a genotyped variant could show different patterns in different populations, due to local variation in haplotype structure and linkage disequilibrium architecture. Furthermore, it is important to emphasize that the genetic basis of susceptibility/resistance to malaria is due to a broad range of susceptibility/protective genes, each resulting in small population effects, which may be missed at low analytical power, such as low allele frequencies. In both cases, the use of larger sample sizes would certainly be of great value.

#### **Population substructure and/or admixture**

Inconsistency of results may also be due to issues of population structure and/or admixture [27]. This is particularly true in African populations, where genetic diversity is exceptionally high. Studies on the same population but in different areas (endemic versus non-endemic regions) have revealed differences in host response to *P. falciparum* [28]. There is also the possible impact of variation in environment (climate, nutritional status) which results in variation of pathogen epidemiology and which becomes more relevant in the rapidly changing socio-economic forces impacting these populations. Furthermore, the lesson learned about genetics of haemoglobinopathies illustrates how distinct malaria resistant alleles have emerged in different populations due to selective pressure, with HbS being found much more endemic in Africa (on four distinct haplotypes) than in Asia, and the opposite for HbE, or again with the relative prevalence of HbS and HbC varying greatly between neighboring countries and even villages [29]. Fine mapping of GW SNP studies in several

different populations, and re-confirmed sequencing of regions of special interest, could provide accurate representations of the genetic background and, therefore, a more effective interpretation of association results.

#### Variation in sampling methodology

Another very important cause of discrepancy is the way severity of malaria is defined. Each of the reported studies classifies malaria severity on the basis of different criteria and thus a common unified and systematic international classification is absolutely needed. This must be considered when studying a large number of individuals across geographical populations. Factors like age may have an important effect on results. Studies that have both children and adults will yield very different results from those involving only adults. The setting where samples are collected may also impact results (urban vs. rural, hospital/clinic based vs. population random cluster sampling).

The establishment of a well-characterized tissue repository with accompanying databases and a robust data-sharing plan would be of great benefit for standardizing phenotype definition, genotyping technology, experimental and analytical plans across multiple sites, to improve the power of the GW studies and ensure reproducibility of the results.

A major driving force in this field of research has been the recent availability of the genome variations data and other information free on line. Databases like *dbSNP* and *Nucleotide*, *Genome* and *Entrez* and *PubMed* among others have helped scientists around the world, especially in Africa, to obtain uniform data on host genetics and infectious diseases. Another factor is the benefit of using high throughput technologies and automated microarrays that can screen whole genomes simultaneously. This kind of costly research will only be possible if serious, consistent and strong collaborative effort is encouraged. Infrastructure to conduct case-controlled GW and multi-centre association studies on malaria susceptibility and resistance must be established where the disease is endemic. Such important studies are very necessary and will provide new insights into the effects of genetic variation on malaria susceptibility and on molecular mechanisms for protective immune responses [30]. However, some studies using these technologies missed some of the significant associations unequivocally determined by classical genetics [24] and the role of regions of the genome involved in malaria resistance, such as alpha-thalassaemia or G6PD deficiency was missed. This raises doubts about the sensitivity of the approach employed. The major limiting factor, at all stages of GW association analysis in Africa, is the need for population-specific data on genome sequence variation. In the near future, this limiting factor should be

overcome by advances in genome sequencing technologies, through initiatives such as the 1000 Genomes Project.

#### Sensitivity of methods

Until GW studies picked up sickle cell trait as a benchmark reference protective factor, utility of these studies in understanding genes associated with malaria severity continues to be limited to identifying only broad associations within the genome. It will be beneficial to use sickle cell trait to assess the power of GWAS. There is also a need for associating gene polymorphism to expressed protein variants using sensitive immunoassay procedures that could identify clusters of biomarker proteins associated with susceptibility and severity of malaria. This approach could be used to establish panels for predicting potentially fatal malaria. Multiplex immunoassay procedures and proteomic technologies should be combined with GWAS and new diagnostics for detecting susceptibility to fatal disease [31]. For example, recent human and murine gene knock out studies suggest that plasma levels of Interferon inducible protein 10 (IP-10; CXCL10) [32], soluble TNF receptor 2 (sTNF-R2) [33] and soluble Fas (sFas) [34] predict risk of malaria related mortality and may be potential biomarkers of CM severity. Additionally, angiogenic factors such as vascular endothelial growth factor (VEGF) were found to be protective against CM associated mortality and may be considered for adjunctive therapy, to improve treatment outcomes in CM patients [35]. Other potential biomarker candidates are interleukin-10 (IL10) and the Granulocyte colony-stimulating factor (G-CSF), cytokines which are associated with susceptibility to asymptomatic malaria during pregnancy [36]. Another recent study has suggested a prominent role for CXCL4 and CXCL10 in the pathogenesis of fatal CM [37]. Clearly, assessment of polymorphisms associated with these significant risk factors or prognostic biomarkers could predict fatal disease outcomes and must be investigated in malaria endemic population. Recent studies have implicated several other genes in the pathogenesis of SMA, CM and placental malarial. It is very important to determine if any gene polymorphisms are associated with these candidate genes.

The Macrophage migration inhibitory factor (MIF) has also been suggested to have a protective role in pathogenesis of malaria [38]. MIF is a multifunctional cytokine which is an important regulator of immune and inflammatory responses in a number of human diseases, such as sepsis, rheumatoid arthritis, cancer and inflammatory neurological diseases [39]. The potential role of MIF in the pathogenesis of malaria anaemia became apparent in an experimental study using a mouse model in which high MIF levels were associated with malaria

anaemia [40]. Human studies conducted on African children reported lower levels of MIF in malaria infected children compared with healthy asymptomatic children [41]. Another study demonstrated a decline in MIF levels during experimental malaria infection using healthy European volunteers [42]. The role of circulating MIF, gene polymorphisms as well as potential interactions with other factors in the pathogenesis of CM and its outcome, need to be further investigated.

#### Role of co-infection in hosts

Several gene pathways reported here are also involved in host responses to bacterial infection. However, caution must be exercised when defining severity phenotype. For example, in high transmission areas most children will have asymptomatic carriage of parasites in their blood such that any acute illness may be ascribed to malaria. It is becoming clear that many of these children carry bacterial sepsis along with the malaria [43]. It will, therefore, be necessary to check for bacterial infection to exclude combined effects during recruitment of volunteer participants in case control studies. Another important factor is to determine whether individual patients have multiple *Plasmodium* infections since each species may present different etiologies. For example, it would be very interesting to determine host factors mediating susceptibility to *Plasmodium vivax* malaria, which is fast becoming recognized as a major cause of SM in Southeast Asia and elsewhere [44,45].

#### Gene polymorphisms associated with multiple diseases

A recent review of gene polymorphisms involved in different phenotypes of sickle cell disease [46] revealed that many genes or pathways mediating sickle cell disease severity are also involved in malaria severity/resistance. For example, the *TNF $\alpha$*  (-308A, rs1800629) polymorphism, which reduces SM, CM, SMA and iron deficiency anaemia, is also protective against large vessel stroke in sickle cell disease. Findings such as these, which reveal genetic similarities across related diseases, will be valuable for identifying important diagnostic biomarkers and for population comparisons.

#### Conclusion

It is clear that genetically-based alterations conferring protection against malaria have led to co-adaptation of various human populations with widespread malaria parasites. This co-adaptative process has resulted in benefits for host (protection) and parasite (reduced virulence/chronicity). A global collaborative effort or consortium must be made to collect information about involvements of biomarkers in malaria susceptibility. This collaboration should include phenotype and clinical data as well as genomics, proteomics, metabolomics and

parasitomics. GW research on protective polymorphisms against malaria will lead to better understanding of the mechanisms underlying malaria severity, which can be used in developing novel therapeutic solutions.

#### Additional material

**Additional file 1: Review of gene polymorphisms reported to date to be significantly associated the host phenotype of susceptibility/resistance to *P. falciparum* malaria.** ↑increase, ↓decrease, SM: Severe Malaria. SMA: Severe Malaria Anaemia. CM: Cerebral Malaria. MM: Mild Malaria. UM: Uncomplicated Malaria [74-121].

**Additional file 2: Summary of gene functions** [122-137].

#### List of abbreviations

SMA: severe malaria anaemia; CM: cerebral malaria; Hb: Haemoglobin; HbAS: Haemoglobin AS or sickle cell trait; G6PD: glucose-6-phosphate dehydrogenase; GW: genome-wide; SM: severe malaria; HLA: human leukocyte antigen system; GWL: genome wide linkage; GWAS: genome wide association studies; SNP: Single Nucleotide Polymorphism; LD: linkage disequilibrium

#### Acknowledgements and Funding

Major support for the biomedical research infrastructure at Morehouse School of Medicine is provided through the Research Centers at Minority Institutions (RCMI) Program, which is sponsored by the National Centers for Research Resources (NCRR) at the National Institutes of Health. Biomedical research technology cores, shared-use facilities, and other resources at MSM have been developed with RCMI funds for use by all MSM scientific investigators. Support from the NIH/Fogarty International Center (FIC) postdoctoral training grant in Genomics and Hemoglobinopathies (NIH-FIC-1R90-G004151-01) and NIH-RCMI (RR033062) are greatly appreciated.

#### Author details

<sup>1</sup>Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA. <sup>2</sup>Department of Urology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. <sup>3</sup>Department of Family Medicine, Morehouse School of Medicine, Atlanta, Georgia, USA.

#### Authors' contributions

AD planned the review, assessed recent studies using different publications research tools, collected and analyzed the data and drafted the manuscript. JM participated in coordination of the review and helped in the critical views of the discussion. NOW, SAI and TVA participated in the design and coordination of the review and corrections and suggestions. JKS participated in the planning, design, coordination, supervision, interpretation of data and revised the manuscript for important intellectual content. All authors helped to draft and correct the manuscript as well as read and approved the final manuscript.

#### Competing interests

The authors declare that they have no competing interests.

Received: 16 May 2011 Accepted: 19 September 2011

Published: 19 September 2011

#### References

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI: **The global distribution of clinical episodes of *Plasmodium falciparum* malaria.** *Nature* 2005, **434**:214-217.
2. Mackinnon MJ, Mwangi TW, Snow RW, Marsh K, Williams TN: **Heritability of malaria in Africa.** *PLoS Med* 2005, **2**:e340.
3. Weatherall DJ, Clegg JB: **Genetic variability in response to infection: malaria and after.** *Genes Immun* 2002, **3**:331-337.
4. Hill AV: **The immunogenetics of resistance to malaria.** *Proc Assoc Am Physicians* 1999, **111**:272-277.

5. Greenwood B, Marsh K, Snow R: **Why do some African children develop severe malaria?** *Parasitol Today* 1991, **7**:277-281.
6. Verra F, Mangano VD, Modiano D: **Genetics of susceptibility to *Plasmodium falciparum*: from classical malaria resistance genes towards genome-wide association studies.** *Parasite Immunol* 2009, **31**:234-253.
7. Allison AC: **Protection afforded by sickle-cell trait against subtertian malarial infection.** *BMJ* 1954, **1**:290-294.
8. Aidoo M, Terlouw DJ, Kolczak MS, McElroy PD, ter Kuile FO, Kariuki S, Nahlen BL, Lal AA, Udhayakumar V: **Protective effects of the sickle cell gene against malaria morbidity and mortality.** *Lancet* 2002, **359**:1311-1312.
9. Allen SJ, Bennett S, Riley EM, Rowe PA, Jakobsen PH, O'Donnell A, Greenwood BM: **Morbidity from malaria and immune responses to defined *Plasmodium falciparum* antigens in children with sickle cell trait in The Gambia.** *Trans R Soc Trop Med Hyg* 1992, **86**:494-498.
10. Le Hesran JY, Personne I, Personne P, Fievet N, Dubois B, Beyeme M, Boudin C, Cot M, Deloron P: **Longitudinal study of *Plasmodium falciparum* infection and immune responses in infants with or without the sickle cell trait.** *Int J Epidemiol* 1999, **28**:793-798.
11. Livingstone FB: **Simulation of the diffusion of the beta-globin variants in the Old World.** *Hum Biol* 1989, **61**:297-309.
12. Kuesap J, Hirayama K, Kikuchi M, Ruangweerayut R, Na-Bangchang K: **Study on association between genetic polymorphisms of haem oxygenase-1, tumour necrosis factor, cadmium exposure and malaria pathogenicity and severity.** *Malar J* 9:260.
13. Garcia-Santos D, Chies JA: **HO-1 polymorphism as a genetic determinant behind the malaria resistance afforded by haemolytic disorders.** *Med Hypotheses* 2010, **74**:807-813.
14. Pamplona A, Ferreira A, Balla J, Jeney V, Balla G, Epiphonio S, Chora A, Rodrigues CD, Gregoire IP, Cunha-Rodrigues M, Portugal S, Soares MP, Mota MM: **Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria.** *Nat Med* 2007, **13**:703-710.
15. Sambo MR, Trovoado MJ, Benchimol C, Quinhentos V, Goncalves L, Velosa R, Marques MI, Sepulveda N, Clark TG, Mustafa S, Wagner O, Coutinho A, Pena-Goncalves C: **Transforming growth factor beta 2 and heme oxygenase 1 genes are risk factors for the cerebral malaria syndrome in Angolan children.** *PLoS One* 5:e11141.
16. Penman BS, Pybus OG, Weatherall DJ, Gupta S: **Epistatic interactions between genetic disorders of hemoglobin can explain why the sickle-cell gene is uncommon in the Mediterranean.** *Proc Natl Acad Sci USA* 2009, **106**:21242-21246.
17. Williams TN, Mwangi TW, Wambua S, Peto TE, Weatherall DJ, Gupta S, Recker M, Penman BS, Uyoga S, Macharia A, Mwacharo JK, Snow RW, Marsh K: **Negative epistasis between the malaria-protective effects of alpha-thalassemia and the sickle cell trait.** *Nat Genet* 2005, **37**:1253-1257.
18. Griffiths MJ, Shafi MJ, Popper SJ, Hemingway CA, Kortok MM, Wathen A, Rockett KA, Mott R, Levin M, Newton CR, Marsh K, Relman DA, Kwiatkowski DP: **Genomewide analysis of the host response to malaria in Kenyan children.** *J Infect Dis* 2005, **191**:1599-1611.
19. Timmann C, Evans JA, Konig IR, Kleensang A, Ruschendorf F, Lenzen J, Sievertsen J, Becker C, Enameh Y, Kwakye KO, Opoku E, Browne EN, Ziegler A, Nurnberg P, Horstmann RD: **Genome-wide linkage analysis of malaria infection intensity and mild disease.** *PLoS Genet* 2007, **3**:e48.
20. Rihet P, Traore Y, Abel L, Aucan C, Traore-Leroux T, Fumoux F: **Malaria in humans: *Plasmodium falciparum* blood infection levels are linked to chromosome 5q31-q33.** *Am J Hum Genet* 1998, **63**:498-505.
21. Sakuntabhai A, Ndiaye R, Casademont I, Peerapittayamongkol C, Rogier C, Tortevoye P, Tall A, Paul R, Turbpaiboon C, Phimpraphi W, Trape JF, Spiegel A, Heath S, Mercereau-Puijalon O, Dieye A, Julier C: **Genetic determination and linkage mapping of *Plasmodium falciparum* malaria related traits in Senegal.** *PLoS One* 2008, **3**:e2000.
22. Ockenhouse CF, Hu WC, Kester KE, Cummings JF, Stewart A, Heppner DG, Jedlicka AE, Scott AL, Wolfe ND, Vahey M, Burke DS: **Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria.** *Infect Immun* 2006, **74**:5561-5573.
23. Torcia MG, Santarlasci V, Cosmi L, Clemente A, Maggi L, Mangano VD, Verra F, Bancone G, Nebie I, Sirima BS, Liotta F, Frosali F, Angeli R, Severini C, Sannella AR, Bonini P, Lucibello M, Maggi E, Garaci E, Coluzzi M, Cozzolino F, Annunziato F, Romagnani S, Modiano D: **Functional deficit of T regulatory cells in Fulani, an ethnic group with low susceptibility to *Plasmodium falciparum* malaria.** *Proc Natl Acad Sci USA* 2008, **105**:646-651.
24. Jallow M, Teo YY, Small KS, Rockett KA, Deloukas P, Clark TG, Kivinen K, Bojang KA, Conway DJ, Pinder M, Sirugo G, Sisay-Joof F, Usen S, Auburn S, Bumpstead SJ, Campino S, Coffey A, Dunham A, Fry AE, Green A, Gwilliam R, Hunt SE, Inouye M, Jeffreys AE, Mendy A, Palotie A, Potter S, Ragoussis J, Rogers J, Rowlands K, Somaskantharajah E, Whittaker P, Widden C, Donnelly P, Howie B, Marchini J, Morris A, Sanjoquin M, Achidi EA, Agbenyega T, Allen A, Amodu O, Corran P, Djimde A, Dolo A, Doumbo OK, Drakeley C, Dunstan S, Evans J, Farrar J, Fernando D, Hien TT, Horstmann RD, Ibrahim M, Karunaweera N, Kokwaro G, Koram KA, Lemnge M, Makani J, Marsh K, Michon P, Modiano D, Molyneux ME, Mueller I, Parker M, Peshu N, Plowe CV, Puijalon O, Reeder J, Reyburn H, Riley EM, Sakuntabhai A, Singhasivanon P, Sirima S, Tall A, Taylor TE, Thera M, Troye-Blomberg M, Williams TN, Wilson M, Kwiatkowski DP, Wellcome Trust Case Control C, Malaria Genomic Epidemiology N: **Genome-wide and fine-resolution association analysis of malaria in West Africa.** *Nat Genet* 2009, **41**:657-665.
25. Guindo A, Fairhurst RM, Doumbo OK, Welles TE, Diallo DA: **X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria.** *PLoS Med* 2007, **4**:e66.
26. Fry AE, Griffiths MJ, Auburn S, Diakite M, Forton JT, Green A, Richardson A, Wilson J, Jallow M, Sisay-Joof F, Pinder M, Peshu N, Williams TN, Marsh K, Molyneux ME, Taylor TE, Rockett KA, Kwiatkowski DP: **Common variation in the ABO glycosyltransferase is associated with susceptibility to severe *Plasmodium falciparum* malaria.** *Hum Mol Genet* 2008, **17**:567-576.
27. Marchini J, Cardon LR, Phillips MS, Donnelly P: **The effects of human population structure on large genetic association studies.** *Nat Genet* 2004, **36**:512-517.
28. Sinha S, Mishra SK, Sharma S, Patibandla PK, Mallick PK, Sharma SK, Mohanty S, Pati SS, Mishra SK, Ramteke BK, Bhatt R, Joshi H, Dash AP, Ahuja RC, Awasthi S, Venkatesh V, Habib S: **Polymorphisms of TNF-enhancer and gene for FcgammaRIIIa correlate with the severity of falciparum malaria in the ethnically diverse Indian population.** *Malar J* 2008, **7**:13.
29. Agarwal A, Guindo A, Cissoko Y, Taylor JG, Coulibaly D, Kone A, Kayentao K, Djimde A, Plowe CV, Doumbo O, Welles TE, Diallo D: **Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S.** *Blood* 2000, **96**:2358-2363.
30. Kwiatkowski DP: **How malaria has affected the human genome and what human genetics can teach us about malaria.** *Am J Hum Genet* 2005, **77**:171-192.
31. Wilson NO, Huang MB, Anderson W, Bond V, Powell M, Thompson WE, Armah HB, Adjei AA, Gyasi R, Tettey Y, Stiles JK: **Soluble factors from *Plasmodium falciparum*-infected erythrocytes induce apoptosis in human brain vascular endothelial and neuroglia cells.** *Mol Biochem Parasitol* 2008, **162**:172-176.
32. Campanella GS, Tager AM, El Khoury JK, Thomas SY, Abrazinski TA, Manice LA, Colvin RA, Luster AD: **Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria.** *Proc Natl Acad Sci USA* 2008, **105**:4814-4819.
33. Lucas R, Juillard P, Decoster E, Redard M, Burger D, Donati Y, Giroud C, Monso-Hinard C, De Kesel T, Buurman WA, Moore MW, Dayer JM, Fiers W, Bluethmann H, Grau GE: **Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria.** *Eur J Immunol* 1997, **27**:1719-1725.
34. Potter SM, Chan-Ling T, Rosinova E, Ball HJ, Mitchell AJ, Hunt NH: **A role for Fas-Fas ligand interactions during the late-stage neuropathological processes of experimental cerebral malaria.** *J Neuroimmunol* 2006, **173**:96-107.
35. Jain V, Armah HB, Tongren JE, Ned RM, Wilson NO, Crawford S, Joel PK, Singh MP, Nagpal AC, Dash AP, Udhayakumar V, Singh N, Stiles JK: **Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India.** *Malar J* 2008, **7**:83.
36. Wilson NO, Bythwood T, Solomon W, Jolly P, Yatich N, Jiang Y, Shuaib F, Adjei AA, Anderson W, Stiles JK: **Elevated levels of IL-10 and G-CSF associated with asymptomatic malaria in pregnant women.** *Infect Dis Obstet Gynecol* 2010.
37. Wilson NO, Jain V, Roberts CE, Lucchi N, Joel PK, Singh MP, Nagpal AC, Dash AP, Udhayakumar V, Singh N, Stiles JK: **CXCL4 and CXCL10 predict risk of fatal cerebral malaria.** *Dis Markers* 30:39-49.

38. Jain V, McClintock S, Nagpal AC, Dash AP, Stiles JK, Udhayakumar V, Singh N, Lucchi NW: **Macrophage migration inhibitory factor is associated with mortality in cerebral malaria patients in India.** *BMC Res Notes* 2009, **2**:36.
39. Lolis E: **Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery.** *Curr Opin Pharmacol* 2001, **1**:662-668.
40. McDevitt MA, Xie J, Shanmugasundaram G, Griffith J, Liu A, McDonald C, Thuma P, Gordeuk VR, Metz CN, Mitchell R, Keefer J, David J, Leng L, Bucala R: **A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia.** *J Exp Med* 2006, **203**:1185-1196.
41. Awandare GA, Hittner JB, Kreamsner PG, Ochiel DO, Keller CC, Weinberg JB, Clark IA, Perkins DJ: **Decreased circulating macrophage migration inhibitory factor (MIF) protein and blood mononuclear cell MIF transcripts in children with *Plasmodium falciparum* malaria.** *Clin Immunol* 2006, **119**:219-225.
42. De Mast Q, Sweep FC, McCall M, Geurts-Moespot A, Hermsen C, Calandra T, Netea MG, Sauerwein RW, van der Ven AJ: **A decrease of plasma macrophage migration inhibitory factor concentration is associated with lower numbers of circulating lymphocytes in experimental *Plasmodium falciparum* malaria.** *Parasite Immunol* 2008, **30**:133-138.
43. Mohan A, Sharma SK, Bollineni S: **Acute lung injury and acute respiratory distress syndrome in malaria.** *J Vector Borne Dis* 2008, **45**:179-193.
44. Price RN, Douglas NM, Anstey NM: **New developments in *Plasmodium vivax* malaria: severe disease and the rise of chloroquine resistance.** *Curr Opin Infect Dis* 2009, **22**:430-435.
45. Sharma VP: **Hidden burden of malaria in Indian women.** *Malar J* 2009, **8**:281.
46. Driss A, Asare KO, Hibbert JM, Gee BE, Adamkiewicz TV, Stiles JK: **Sickle cell disease in the post genomic era: a monogenic disease with a polygenic phenotype.** *Genomics Insights* 2009, **2009**:23-48.
47. Modiano D, Luoni G, Sirima BS, Simpore J, Verra F, Konate A, Rastrelli E, Olivieri A, Calissano C, Paganotti GM, D'Urbano L, Sanou I, Sawadogo A, Modiano G, Coluzzi M: **Haemoglobin C protects against clinical *Plasmodium falciparum* malaria.** *Nature* 2001, **414**:305-308.
48. Hutagalung R, Wilairatana P, Looareesuwan S, Brittenham GM, Aikawa M, Gordeuk VR: **Influence of hemoglobin E trait on the severity of *Falci-parum* malaria.** *J Infect Dis* 1999, **179**:283-286.
49. Chotivanich K, Udomsangpetch R, Pattanapanyasat K, Chierakul W, Simpson J, Looareesuwan S, White N: **Hemoglobin E: a balanced polymorphism protective against high parasitemias and thus severe *P falciparum* malaria.** *Blood* 2002, **100**:1172-1176.
50. Cholera R, Brittain NJ, Gillrie MR, Lopera-Mesa TM, Diakite SA, Arie T, Krause MA, Guindo A, Tubman A, Fujioka H, Diallo DA, Doumbo OK, Ho M, Wellem's TE, Fairhurst RM: **Impaired cytoadherence of *Plasmodium falciparum*-infected erythrocytes containing sickle hemoglobin.** *Proc Natl Acad Sci USA* 2008, **105**:991-996.
51. Allen SJ, O'Donnell A, Alexander ND, Alpers MP, Peto TE, Clegg JB, Weatherall DJ: **alpha+-Thalassemia protects children against disease caused by other infections as well as malaria.** *Proc Natl Acad Sci USA* 1997, **94**:14736-14741.
52. May J, Evans JA, Timmann C, Ehmen C, Busch W, Thye T, Agbenyega T, Horstmann RD: **Hemoglobin variants and disease manifestations in severe *falciparum* malaria.** *JAMA* 2007, **297**:2220-2226.
53. Fowkes FJ, Allen SJ, Allen A, Alpers MP, Weatherall DJ, Day KP: **Increased microerythrocyte count in homozygous alpha(+)-thalassaemia contributes to protection against severe malarial anaemia.** *PLoS Med* 2008, **5**:e56.
54. Luzzi GA, Merry AH, Newbold CI, Marsh K, Pasvol G: **Protection by alpha-thalassaemia against *Plasmodium falciparum* malaria: modified surface antigen expression rather than impaired growth or cytoadherence.** *Immunol Lett* 1991, **30**:233-240.
55. Pasvol G, Wilson RJ: **The interaction of malaria parasites with red blood cells.** *Br Med Bull* 1982, **38**:133-140.
56. Tishkoff SA, Varkonyi R, Cahinhan N, Abbes S, Argyropoulos G, Destro-Bisol G, Drousiotou A, Dargerfield B, Lefranc G, Loiselet J, Piro A, Stoneking M, Tagarelli A, Tagarelli G, Touma EH, Williams SM, Clark AG: **Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance.** *Science* 2001, **293**:455-462.
57. Allison AC, Clyde DF: **Malaria in African children with deficient erythrocyte glucose-6-phosphate dehydrogenase.** *Br Med J* 1961, **1**:1346-1349.
58. Bienzle U, Ayeni O, Lucas AO, Luzzatto L: **Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant.** *Lancet* 1972, **1**:107-110.
59. Ruwende C, Khoo SC, Snow RW, Yates SN, Kwiatkowski D, Gupta S, Warn P, Allsopp CE, Gilbert SC, Peschu N, Newbold CI, Greenwood BM, Marsh K, Hill AVS: **Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria.** *Nature* 1995, **376**:246-249.
60. Durand PM, Coetzer TL: **Pyruvate kinase deficiency protects against malaria in humans.** *Haematologica* 2008, **93**:939-940.
61. Cortes A, Benet A, Cooke BM, Barnwell JW, Reeder JC: **Ability of *Plasmodium falciparum* to invade Southeast Asian ovalocytes varies between parasite lines.** *Blood* 2004, **104**:2961-2966.
62. Cortes A, Mellombo M, Mgone CS, Beck HP, Reeder JC, Cooke BM: **Adhesion of *Plasmodium falciparum*-infected red blood cells to CD36 under flow is enhanced by the cerebral malaria-protective trait South-East Asian ovalocytosis.** *Mol Biochem Parasitol* 2005, **142**:252-257.
63. Facer CA: **Erythrocytes carrying mutations in spectrin and protein 4.1 show differing sensitivities to invasion by *Plasmodium falciparum*.** *Parasitol Res* 1995, **81**:52-57.
64. Wang HY, Tang H, Shen CK, Wu CI: **Rapidly evolving genes in human. I. The glycophorins and their possible role in evading malaria parasites.** *Mol Biol Evol* 2003, **20**:1795-1804.
65. Blumenfeld S: **Reflections on effective leadership: strains and successes, strategies and styles.** *Soc Work Health Care* 1995, **20**:21-37.
66. Rowe JA, Handel IG, Thera MA, Deans AM, Lyke KE, Kone A, Diallo DA, Raza A, Kai O, Marsh K, Plowe CV, Doumbo OK, Moulds JM: **Blood group O protects against severe *Plasmodium falciparum* malaria through the mechanism of reduced rosetting.** *Proc Natl Acad Sci USA* 2007, **104**:17471-17476.
67. Barragan A, Kreamsner PG, Wahlgren M, Carlson J: **Blood group A antigen is a coreceptor in *Plasmodium falciparum* rosetting.** *Infect Immun* 2000, **68**:2971-2975.
68. Pare G, Chasman DI, Kellogg M, Zee RY, Rifai N, Badola S, Miletich JP, Ridker PM: **Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.** *PLoS Genet* 2008, **4**:e1000118.
69. Elagib AA, Kider AO, Akerstrom B, Elbashir MI: **Association of the haptoglobin phenotype (1-1) with *falciparum* malaria in Sudan.** *Trans R Soc Trop Med Hyg* 1998, **92**:309-311.
70. Quaye IK, Ekuban FA, Goka BQ, Adabayeri V, Kurtzhals JA, Gyan B, Ankrah NA, Hviid L, Akanmori BD: **Haptoglobin 1-1 is associated with susceptibility to severe *Plasmodium falciparum* malaria.** *Trans R Soc Trop Med Hyg* 2000, **94**:216-219.
71. Cox SE, Doherty C, Atkinson SH, Nweneka CV, Fulford AJ, Ghattas H, Rockett KA, Kwiatkowski DP, Prentice AM: **Haplotype association between haptoglobin (Hp2) and Hp promoter SNP (A-61C) may explain previous controversy of haptoglobin and malaria protection.** *PLoS One* 2007, **2**: e362.
72. Kun JF, Mordmuller B, Perkins DJ, May J, Mercereau-Pujalon O, Alpers M, Weinberg JB, Kreamsner PG: **Nitric oxide synthase 2(Lambarene) (G-954C), increased nitric oxide production, and protection against malaria.** *J Infect Dis* 2001, **184**:330-336.
73. Hobbs MR, Udhayakumar V, Levesque MC, Booth J, Roberts JM, Tkachuk AN, Pole A, Coon H, Kariuki S, Nahlen BL, Mwaikambo ED, Lal AL, Granger DL, Anstey NM, Weinberg JB: **A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children.** *Lancet* 2002, **360**:1468-1475.
74. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM: **Common west African HLA antigens are associated with protection from severe malaria.** *Nature* 1991, **352**:595-600.
75. Gilbert SC, Plebanski M, Gupta S, Morris J, Cox M, Aidoo M, Kwiatkowski D, Greenwood BM, Whittle HC, Hill AV: **Association of malaria parasite population structure, HLA, and immunological antagonism.** *Science* 1998, **279**:1173-1177.



76. Young K, Frodsham A, Doumbo OK, Gupta S, Dolo A, Hu JT, Robson KJ, Crisanti A, Hill AV, Gilbert SC: **Inverse associations of human leukocyte antigen and malaria parasite types in two West African populations.** *Infect Immun* 2005, **73**:953-955.
77. McGuire W, Knight JC, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D: **Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles.** *J Infect Dis* 1999, **179**:287-290.
78. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D: **Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria.** *Nature* 1994, **371**:508-510.
79. Atkinson SH, Rockett KA, Morgan G, Bejon PA, Sirugo G, O'Connell MA, Hanchard N, Kwiatkowski DP, Prentice AM: **Tumor necrosis factor SNP haplotypes are associated with iron deficiency anemia in West African children.** *Blood* 2008, **112**:4276-4283.
80. Cabantous S, Poudioungou B, Traore A, Keita M, Cisse MB, Doumbo O, Dessein AJ, Marquet S: **Evidence that interferon-gamma plays a protective role during cerebral malaria.** *J Infect Dis* 2005, **192**:854-860.
81. Koch O, Awomoyi A, Usen S, Jallow M, Richardson A, Hull J, Pinder M, Newport M, Kwiatkowski D: **IFNGR1 gene promoter polymorphisms and susceptibility to cerebral malaria.** *J Infect Dis* 2002, **185**:1684-1687.
82. Mangano VD, Luoni G, Rockett KA, Sirima BS, Konate A, Forton J, Clark TG, Bancone G, Sadighi Akha E, Kwiatkowski DP, Modiano D: **Interferon regulatory factor-1 polymorphisms are associated with the control of *Plasmodium falciparum* infection.** *Genes Immun* 2008, **9**:122-129.
83. Mangano VD, Clark TG, Auburn S, Campino S, Diakite M, Fry AE, Green A, Richardson A, Jallow M, Sisay-Joof F, Pinder M, Griffiths MJ, Newton C, Peshu N, Williams TN, Marsh K, Molyneux ME, Taylor TE, Modiano D, Kwiatkowski DP, Rockett KA: **Lack of association of interferon regulatory factor 1 with severe malaria in affected child-parental trio studies across three African populations.** *PLoS One* 2009, **4**:e4206.
84. Sabeti P, Usen S, Farhadian S, Jallow M, Doherty T, Newport M, Pinder M, Ward R, Kwiatkowski D: **CD40L association with protection from severe malaria.** *Genes Immun* 2002, **3**:286-291.
85. Walley AJ, Aucan C, Kwiatkowski D, Hill AV: **Interleukin-1 gene cluster polymorphisms and susceptibility to clinical malaria in a Gambian case-control study.** *Eur J Hum Genet* 2004, **12**:132-138.
86. Gyan B, Goka B, Cvetkovic JT, Perlmann H, Lefvert AK, Akanmori B, Troye-Blomberg M: **Polymorphisms in interleukin-1beta and interleukin-1 receptor antagonist genes and malaria in Ghanaian children.** *Scand J Immunol* 2002, **56**:619-622.
87. Ohashi J, Naka I, Doi A, Patarapotikul J, Hananantachai H, Tangpukdee N, Looareesuwan S, Tokunaga K: **A functional polymorphism in the IL1B gene promoter, IL1B -31C > T, is not associated with cerebral malaria in Thailand.** *Malar J* 2005, **4**:38.
88. Luoni G, Verra F, Arca B, Sirima BS, Troye-Blomberg M, Coluzzi M, Kwiatkowski D, Modiano D: **Antimalarial antibody levels and IL4 polymorphism in the Fulani of West Africa.** *Genes Immun* 2001, **2**:411-414.
89. Verra F, Luoni G, Calissano C, Troye-Blomberg M, Perlmann P, Perlmann H, Arca B, Sirima BS, Konate A, Coluzzi M, Kwiatkowski D, Modiano D: **IL4-589C/T polymorphism and IgE levels in severe malaria.** *Acta Trop* 2004, **90**:205-209.
90. Vafa M, Maiga B, Berzins K, Hayano M, Bereczky S, Dolo A, Daou M, Arama C, Kouriba B, Farnert A, Doumbo OK, Troye-Blomberg M: **Associations between the IL-4 -590 T allele and *Plasmodium falciparum* infection prevalence in asymptomatic Fulani of Mali.** *Microbes Infect* 2007, **9**:1043-1048.
91. Tangteerawatana P, Pichyangkul S, Hayano M, Kalambaheti T, Looareesuwan S, Troye-Blomberg M, Khusmith S: **Relative levels of IL4 and IFN-gamma in complicated malaria: association with IL4 polymorphism and peripheral parasitemia.** *Acta Trop* 2007, **101**:258-265.
92. Gyan BA, Goka B, Cvetkovic JT, Kurtzhals JL, Adabayeri V, Perlmann H, Lefvert AK, Akanmori BD, Troye-Blomberg M: **Allelic polymorphisms in the repeat and promoter regions of the interleukin-4 gene and malaria severity in Ghanaian children.** *Clin Exp Immunol* 2004, **138**:145-150.
93. Ouma C, Davenport GC, Were T, Otieno MF, Hittner JB, Vulule JM, Martinson J, Ong'echa JM, Ferrrell RE, Perkins DJ: **Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production.** *Hum Genet* 2008, **124**:515-524.
94. Koch O, Rockett K, Jallow M, Pinder M, Sisay-Joof F, Kwiatkowski D: **Investigation of malaria susceptibility determinants in the IFNG/IL26/IL22 genomic region.** *Genes Immun* 2005, **6**:312-318.
95. Nasr A, Iriemenam NC, Giha HA, Balogun HA, Anders RF, Troye-Blomberg M, ElGhazali G, Berzins K: **FcgammaRIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan.** *Malar J* 2009, **8**:43.
96. Shi YP, Nahlen BL, Kariuki S, Urdahl KB, McElroy PD, Roberts JM, Lal AA: **Fcgamma receptor IIa (CD32) polymorphism is associated with protection of infants against high-density *Plasmodium falciparum* infection. VII. Asembo Bay Cohort Project.** *J Infect Dis* 2001, **184**:107-111.
97. Nasr A, Iriemenam NC, Troye-Blomberg M, Giha HA, Balogun HA, Osman OF, Montgomery SM, ElGhazali G, Berzins K: **Fc gamma receptor IIa (CD32) polymorphism and antibody responses to asexual blood-stage antigens of *Plasmodium falciparum* malaria in Sudanese patients.** *Scand J Immunol* 2007, **66**:87-96.
98. Cooke GS, Aucan C, Walley AJ, Segal S, Greenwood BM, Kwiatkowski DP, Hill AV: **Association of Fcgamma receptor IIa (CD32) polymorphism with severe malaria in West Africa.** *Am J Trop Med Hyg* 2003, **69**:565-568.
99. Omi K, Ohashi J, Patarapotikul J, Hananantachai H, Naka I, Looareesuwan S, Tokunaga K: **Absence of association between the Fc gamma receptor IIIA-176F/V polymorphism and the severity of malaria in Thai.** *Jpn J Infect Dis* 2002, **55**:167-169.
100. Clatworthy MR, Willcocks L, Urban B, Langhorne J, Williams TN, Peshu N, Watkins NA, Floto RA, Smith KG: **Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria.** *Proc Natl Acad Sci USA* 2007, **104**:7169-7174.
101. Mockenhaupt FP, Hamann L, von Gaertner C, Bedu-Addo G, von Kleinsorgen C, Schumann RR, Bienzle U: **Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy.** *J Infect Dis* 2006, **194**:184-188.
102. Leoratti FM, Farias L, Alves FP, Suarez-Mutis MC, Coura JR, Kalil J, Camargo EP, Moraes SL, Ramasawmy R: **Variants in the toll-like receptor signaling pathway and clinical outcomes of malaria.** *J Infect Dis* 2008, **198**:772-780.
103. Hamann L, Kumpf O, Schuring RP, Alpsyoy E, Bedu-Addo G, Bienzle U, Oskam L, Mockenhaupt FP, Schumann RR: **Low frequency of the TIRAP S180L polymorphism in Africa, and its potential role in malaria, sepsis, and leprosy.** *BMC Med Genet* 2009, **10**:65.
104. Uhlemann AC, Szlezak NA, Vonthein R, Tomiuk J, Emmer SA, Lell B, Kreamsner PG, Kun JF: **DNA phasing by TA dinucleotide microsatellite length determines in vitro and in vivo expression of the gp91phox subunit of NADPH oxidase and mediates protection against severe malaria.** *J Infect Dis* 2004, **189**:2227-2234.
105. Luty AJ, Kun JF, Kreamsner PG: **Mannose-binding lectin plasma levels and gene polymorphisms in *Plasmodium falciparum* malaria.** *J Infect Dis* 1998, **178**:1221-1224.
106. Garred P, Nielsen MA, Kurtzhals JA, Malhotra R, Madsen HO, Goka BQ, Akanmori BD, Sim RB, Hviid L: **Mannose-binding lectin is a disease modifier in clinical malaria and may function as opsonin for *Plasmodium falciparum*-infected erythrocytes.** *Infect Immun* 2003, **71**:5245-5253.
107. Holmberg V, Schuster F, Dietz E, Sagarriga Visconti JC, Anemana SD, Bienzle U, Mockenhaupt FP: **Mannose-binding lectin variant associated with severe malaria in young African children.** *Microbes Infect* 2008, **10**:342-348.
108. Rowe JA, Moulds JM, Newbold CI, Miller LH: ***P. falciparum* rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1.** *Nature* 1997, **388**:292-295.
109. Cockburn IA, Mackinnon MJ, O'Donnell A, Allen SJ, Moulds JM, Baisor M, Bockarie M, Reeder JC, Rowe JA: **A human complement receptor 1 polymorphism that reduces *Plasmodium falciparum* rosetting confers protection against severe malaria.** *Proc Natl Acad Sci USA* 2004, **101**:272-277.
110. Sinha S, Qidwai T, Kanchan K, Anand P, Jha GN, Pati SS, Mohanty S, Mishra SK, Tyagi PK, Sharma SK, Venkatesh V, Habib S: **Variations in host genes encoding adhesion molecules and susceptibility to falciparum malaria in India.** *Malar J* 2008, **7**:250.
111. Amodu OK, Gbadegesin RA, Ralph SA, Adeyemo AA, Brenchley PE, Ayoola OO, Orimadegun AE, Akinsola AK, Olumese PE, Omotade OO: ***Plasmodium falciparum* malaria in south-west Nigerian children: is the**

- polymorphism of ICAM-1 and E-selectin genes contributing to the clinical severity of malaria? *Acta Trop* 2005, **95**:248-255.
112. Fry AE, Auburn S, Diakite M, Green A, Richardson A, Wilson J, Jallow M, Sisay-Joof F, Pinder M, Griffiths MJ, Peshu N, Williams TN, Marsh K, Molyneux ME, Taylor TE, Rockett KA, Kwiatkowski DP: **Variation in the ICAM1 gene is not associated with severe malaria phenotypes.** *Genes Immun* 2008, **9**:462-469.
113. Ndiaye R, Sakuntabhai A, Casademont I, Rogier C, Tall A, Trape JF, Spiegel A, Dieye A, Julier C: **Genetic study of ICAM1 in clinical malaria in Senegal.** *Tissue Antigens* 2005, **65**:474-480.
114. Kun JF, Lehman LG, Lell B, Schmidt-Ott R, Kremsner PG: **Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug-resistant *Plasmodium falciparum* strains.** *Antimicrob Agents Chemother* 1999, **43**:2205-2208.
115. Fernandez-Reyes D, Craig AG, Kyes SA, Peshu N, Snow RW, Berendt AR, Marsh K, Newbold CI: **A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya.** *Hum Mol Genet* 1997, **6**:1357-1360.
116. Kikuchi M, Looareesuwan S, Ubalee R, Tسانور O, Suzuki F, Wattanagoon Y, Na-Bangchang K, Kimura A, Aikawa M, Hirayama K: **Association of adhesion molecule PECAM-1/CD31 polymorphism with susceptibility to cerebral malaria in Thais.** *Parasitol Int* 2001, **50**:235-239.
117. Casals-Pascual C, Allen S, Allen A, Kai O, Lowe B, Pain A, Roberts DJ: **Short report: codon 125 polymorphism of CD31 and susceptibility to malaria.** *Am J Trop Med Hyg* 2001, **65**:736-737.
118. Omi K, Ohashi J, Patarapotikul J, Hananantachai H, Naka I, Looareesuwan S, Tokunaga K: **CD36 polymorphism is associated with protection from cerebral malaria.** *Am J Hum Genet* 2003, **72**:364-374.
119. Aitman TJ, Cooper LD, Norsworthy PJ, Wahid FN, Gray JK, Curtis BR, McKeigue PM, Kwiatkowski D, Greenwood BM, Snow RW, Hill AV, Scott J: **Malaria susceptibility and CD36 mutation.** *Nature* 2000, **405**:1015-1016.
120. Pain A, Urban BC, Kai O, Casals-Pascual C, Shafi J, Marsh K, Roberts DJ: **A non-sense mutation in Cd36 gene is associated with protection from severe malaria.** *Lancet* 2001, **357**:1502-1503.
121. Sikora M, Ferrer-Admetlla A, Laayouni H, Menendez C, Mayor A, Bardaji A, Sigauque B, Mandomando I, Alonso PL, Bertranpetit J, Casals F: **A variant in the gene FUT9 is associated with susceptibility to placental malaria infection.** *Hum Mol Genet* 2009, **18**:3136-3144.
122. Kwiatkowski D, Hill AV, Sambou I, Twumasi P, Castracane J, Manogue KR, Cerami A, Brewster DR, Greenwood BM: **TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated *Plasmodium falciparum* malaria.** *Lancet* 1990, **336**:1201-1204.
123. Grau GE, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, Hommel M, Lambert PH: **Tumor necrosis factor and disease severity in children with falciparum malaria.** *N Engl J Med* 1989, **320**:1586-1591.
124. Charoenvit Y, Majam VF, Corradin G, Sacchi JB Jr, Wang R, Doolan DL, Jones TR, Abot E, Patarroyo ME, Guzman F, Hoffman SL: **CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a *Plasmodium yoelii* 17-kilodalton hepatocyte erythrocyte protein.** *Infect Immun* 1999, **67**:5604-5614.
125. Luty AJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, Matousek P, Herbich K, Schmid D, Migot-Nabias F, Deloron P, Nussenzweig RS, Kremsner PG: **Interferon-gamma responses are associated with resistance to reinfection with *Plasmodium falciparum* in young African children.** *J Infect Dis* 1999, **179**:980-988.
126. Bach EA, Aguet M, Schreiber RD: **The IFN gamma receptor: a paradigm for cytokine receptor signaling.** *Annu Rev Immunol* 1997, **15**:563-591.
127. Lohoff M, Mak TW: **Roles of interferon-regulatory factors in T-helper-cell differentiation.** *Nat Rev Immunol* 2005, **5**:125-135.
128. Sabeti PC, Reich DE, Higgins JM, Levine HZ, Richter DJ, Schaffner SF, Gabriel SB, Platko JV, Patterson NJ, McDonald GJ, Ackerman HC, Campbell SJ, Altshuler D, Cooper R, Kwiatkowski D, Ward R, Lander ES: **Detecting recent positive selection in the human genome from haplotype structure.** *Nature* 2002, **419**:832-837.
129. Dunn E, Sims JE, Nicklin MJ, O'Neill LA: **Annotating genes with potential roles in the immune system: six new members of the IL-1 family.** *Trends Immunol* 2001, **22**:533-536.
130. Marsh DG, Neely JD, Breazeale DR, Ghosh B, Freidhoff LR, Ehrlich-Kautzky E, Schou C, Krishnaswamy G, Beaty TH: **Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations.** *Science* 1994, **264**:1152-1156.
131. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB: **Interleukin-10 and related cytokines and receptors.** *Annu Rev Immunol* 2004, **22**:929-979.
132. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R: **IL-22 increases the innate immunity of tissues.** *Immunity* 2004, **21**:241-254.
133. Bolland S, Ravetch JV: **Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis.** *Immunity* 2000, **13**:277-285.
134. Akira S, Takeda K: **Functions of toll-like receptors: lessons from KO mice.** *C R Biol* 2004, **327**:581-589.
135. Bekeredjian-Ding I, Jego G: **Toll-like receptors-sentries in the B-cell response.** *Immunology* 2009, **128**:311-323.
136. Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, Yamamoto M, Takeuchi O, Itagaki S, Kumar N, Horii T, Akira S: **Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin.** *J Exp Med* 2005, **201**:19-25.
137. Treutiger CJ, Heddi A, Fernandez V, Muller WA, Wahlgren M: **PECAM-1/CD31, an endothelial receptor for binding *Plasmodium falciparum*-infected erythrocytes.** *Nat Med* 1997, **3**:1405-1408.

doi:10.1186/1475-2875-10-271

Cite this article as: Driss et al.: Genetic polymorphisms linked to susceptibility to malaria. *Malaria Journal* 2011 **10**:271.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

